4-(5-(3-HYDROXYPROPYL)-4-(2-PHENYETHYL)-1,3-THIAZOL-2-YL]-1-[(3-PHENYLPROPYL)THIO]BUTAN-2-ONE


Molecule Category	Free-form
Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	BJRKTVHPLBHMBP-UHFFFAOYSA-N
Smiles	OCCCc1sc(CCC(=O)CSCCCc2ccccc2)nc1CCc3ccccc3
InChI	InChI=1S/C27H33NO2S2/c29-19-7-14-26-25(17-15-23-11-5-2-6-12-23)28-27(32-26)18-16-24(30)21-31-20-8-13-22-9-3-1-4-10-22/h1-6,9-12,29H,7-8,13-21H2

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C27H33NO2S2
Molecular Weight	467.69
AlogP	5.81
Hydrogen Bond Acceptor	4.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	15.0
Polar Surface Area	103.73
Molecular species	NEUTRAL
Aromatic Rings	3.0
Heavy Atoms	32.0

Assay Description	Organism	Bioactivity
Inhibition of recombinant Plasmodium falciparum falcipain-3 using Z-Leu-Arg-AMC as substrate compound treated for 30 min before substrate addition by fluorescence assay	Plasmodium falciparum	50000.0 nM
Inhibition of recombinant Plasmodium falciparum falcipain-2 using Z-Leu-Arg-AMC as substrate compound treated for 30 min before substrate addition by fluorescence assay	Plasmodium falciparum	12500.0 nM
Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells by Neutral Red assay	Chlorocebus aethiops	40.6 uM
Antileishmanial activity against Leishmania donovani promastigotes after 72 hr by alamar blue assay	Leishmania donovani	16300.0 nM
Antimalarial activity against Plasmodium falciparum W2 after 72 hr by LDH assay	Plasmodium falciparum	19100.0 nM
Antimalarial activity against Plasmodium falciparum D6 after 72 hr by LDH assay	Plasmodium falciparum D6	20300.0 nM

Cross References

Resources	Reference
ChEMBL	CHEMBL2260629
PubChem	71463489

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).